5-HO-DPT, also known as 5-hydroxy-N,N-dipropyltryptamine, as well as N,N-dipropylserotonin (DiPS or NDPS), is a serotonin receptor modulator of the tryptamine and 5-hydroxytryptamine families. It is the N,N-dipropyl derivative of serotonin (5-hydroxytryptamine; 5-HT).
The drug shows affinity for the serotonin 5-HT<sub>1A</sub> receptor (K<sub>i</sub> = 7.1nM), the serotonin 5-HT<sub>1B</sub> receptor (K<sub>i</sub> = 4,300nM), and the serotonin 5-HT<sub>2</sub> receptor (K<sub>i</sub> = 1.0âÂÂ450nM). 5-HO-DPT was not tested itself, but its O-methyl ether 5-MeO-DPT fully substituted for the psychedelic drug DOM in rodent drug discrimination tests and partially substituted for 8-OH-DPAT in these tests followed by behavioral disruption at higher doses.
5-Hydroxytryptamines like bufotenin (5-HO-DMT) are known to be hydrophilic and peripherally selective, in turn resulting in difficulty crossing the bloodâÂÂbrain barrier and exerting central effects. However, 5-HO-DPT is notable in having much greater lipophilicity in comparison to bufotenin owing to its propyl groups (predicted log P = 3.0 and 1.2, respectively).
Analogues of 5-HO-DPT include dipropyltryptamine (DPT), 4-HO-DPT (deprocin), 4-AcO-DPT (depracetin), 5-MeO-DPT, bufotenin (5-HO-DMT), 5-HO-MET, 5-HO-DET, and 5-HO-DiPT, among others.
5-HO-DPT was first described in the scientific literature by Richard Glennon and colleagues by 1988.